Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC
Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).
Dr. Lipson on the Current Treatment Landscape of Basal Cell Carcinoma
Evan J. Lipson, MD, discusses the current treatment landscape in locally advanced, unresectable, or metastatic basal cell carcinoma.
Dr. Lipson on the Role of ctDNA Testing in Melanoma
Evan J. Lipson, MD, discusses the role of circulating tumor DNA testing in melanoma.
Emerging Treatments for Advanced Melanoma
Long-Term Survival Data in Adjuvant Therapy
Metastatic Melanoma Long-Term Survival Data
BRAF-Wild Type vs Mutated Unresectable Melanoma
Short-Term COVID-19 NCCN Recommendations
Balancing Safety and Efficacy in Adjuvant Therapy
Adjuvant Therapy in Stage IIIB/IIIC/IIID Melanoma
Adjuvant Clinical Trial Data Impact on Treatment Selection
Importance of Molecular Testing in Stage III Melanoma
Neoadjuvant Melanoma Therapy: Patient Selection
Impact of MSLT-II Data on Completion Lymph Node Dissection
The Optimal Approach to Treating Advanced Melanoma
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512